PYFA - PT. Pyridam Farma Tbk

Rp 1.035

-5 (0%)

JAKARTA. PT Pyridam Farma Tbk (PYFA) set the target of revenue and net profit growth to reach 50%, following positive trends in its performance throughout the first three months of 2021.

PYFA scored IDR 117.4 billion in sales in the first quarter of 2021. It was 49% higher than the sales reported in the same period last year. These sales then sent the EBITDA skyrocketing 225% to IDR 26.4 billion, while its net profit massively proliferated by 149% to IDR 10.9 billion.

The pharmaceutical products, services, and toll manufacturing sector generated net sales of IDR 108.8 billion, increasing 20% from the number reported in the same quarter last year. Then, the medical equipment sector tails with IDR 28 billion after a massive surge of 585%.

The medical equipment in question mainly comprises supporting products for PCR test kits, including the syringes and other tools related to COVID-19 treatment. Yenfrino Gunadi, Financial Director of Pyridam Farma, revealed this information through a public expose yesterday (25/8). (AM/ZH)